![]() |
½ÃÀ庸°í¼
»óÇ°ÄÚµå
1381103
SAGE-217 ½Å±Ô ¾àÁ¦ ÀλçÀÌÆ®¿Í ½ÃÀå ¿¹Ãø(2032³â)SAGE-217 Emerging Drug Insight and Market Forecast - 2032 |
Zuranolone(SAGE-217)Àº »êÈÄ¿ì¿ïÁõ(PPD) Ä¡·áÁ¦·Î °³¹ßÁßÀÎ °æ±¸¿ë ½Å¾àÀ¸·Î, 1ÀÏ 1ȸ 2ÁÖ°£ Åõ¿©ÇÏ´Â ½Å°æÈ°¼º½ºÅ×·ÎÀ̵å(NAS) GABAA ¼ö¿ëü ¾ç¼º µ¿Á¾Á¶ÀýÁ¦(PAM)·Î PPD, ÁÖ¿ä¿ì¿ïÀå¾Ö(MDD), Ä¡·á ÀúÇ×¼º ¿ì¿ïÁõÀ» Æ÷ÇÔÇÑ ¿©·¯ ¿ì¿ïÀå¾Ö¸¦ ¿ÏÈÇϱâ À§ÇØ Æ¯º°È÷ °í¾ÈµÈ ¾à¹°ÀÔ´Ï´Ù. GABA ½Ã½ºÅÛÀº ³úÀÇ ÁÖ¿ä ¾ïÁ¦¼º ½ÅÈ£ Àü´Þ °æ·ÎÀ̸ç ÁßÃß ½Å°æ°è(CNS)´Â CNS ±â´ÉÀ» ÇöÀúÇÏ°Ô Á¶ÀýÇÕ´Ï´Ù. SAGE-217Àº ½Ã³À½º ¹× ½Ã³À½º ¿Ü AÇü ¥ã- ¾Æ¹Ì³ë ºÎƼ¸£»ê(GABAA) ¼ö¿ëü¿¡ ´ëÇÑ ¼±Åüº°ú 1,000 °³ÀÇ(GABAA) ¼ö¿ëü¿¡ ´ëÇÑ ¼±Åüº°ú 1ÀÏ 1ȸ °æ±¸ Åõ¿©¿¡ ÀûÇÕÇÑ ¾àµ¿ÇÐÀû ÇÁ·ÎÆÄÀÏ¿¡ ÃÖÀûȵǾî ÀÖ½À´Ï´Ù.
¾ÕÀ¸·Î ¼ö³â°£ »êÈÄ¿ì¿ïÁõ(PPD) ½ÃÀå ½Ã³ª¸®¿À´Â ¼¼°è¿¡¼ ±¤¹üÀ§ÇÑ Á¶»ç¿Í ÀÇ·áºñ ÁöÃâ Áõ°¡·Î ÀÎÇØ º¯ÈÇÒ °ÍÀÔ´Ï´Ù. °¢ ȸ»ç´Â Áúº´À» Ä¡·á/°³¼±Çϱâ À§ÇÑ »õ·Î¿î Á¢±Ù ¹æ½Ä¿¡ ÃÊÁ¡À» ¸ÂÃá Ä¡·á¹ýÀ» °³¹ßÇÏ°í, °úÁ¦¸¦ Æò°¡ÇÏ°í, SAGE-217ÀÇ ¿ìÀ§¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ±âȸ¸¦ ¸ð»öÇÏ°í ÀÖÀ¸¸ç, PPD¿¡ ´ëÇÑ ´Ù¸¥ ½ÅÈï Á¦Ç°ÀÌ SAGE-217°ú Ä¡¿ÇÑ ½ÃÀå °æÀïÀ» ¹úÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù, ÈĹßÁÖÀÚ ½Å¾àÀÌ Ãâ½ÃµÇ¸é ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹Ì±¹ÀÇ SAGE-217 ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, »êÈÄ ¿ì¿ïÁõ(PPD) Ä¡·áÁ¦ÀÎ SAGE-217 ½ÃÀåÀÇ °³¿ä¿Í 2023-2032³â ÆǸŠ¿¹Ãø µ¥ÀÌÅÍ, °æÀï ±¸µµ µîÀ» Á¦°øÇÏ°í ÀÖ½À´Ï´Ù.
“"SAGE-217 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SAGE-217 for Postpartum depression (PPD) in the United States. A detailed picture of the SAGE-217 for PPD in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the SAGE-217 for PPD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAGE-217 market forecast analysis for PPD in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PPD.
Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type A γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of SAGE-217 for postpartum depression (PPD) in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of SAGE-217 for PPD covering trial interventions, trial conditions, trial status, start and completion dates.